BFA
VRTX icon

Brown Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Brown Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$956K Sell
2,141
-227
-10% -$106K 0.36% 82
2025
Q4 		$1.07M Buy
2,368
+39
+2% +$16.8K 0.39% 87
2025
Q3 		$912K Buy
2,329
+76
+3% +$31.8K 0.34% 88
2025
Q2 		$1M Buy
+2,253
New +$1.04M 0.39% 88

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Brown Financial Advisors's VRTX Position: Q1 2026 in Review

Brown Financial Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 9.6% in Q1 2026, selling an estimated $106K and leaving 2,141 shares worth $956K. The position accounts for 0.36% of the portfolio, ranked #82.

Brown Financial Advisors first reported a position in VRTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.07M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Brown Financial Advisors held 2,141 shares of Vertex Pharmaceuticals worth $956K as of Q1 2026.
  • Brown Financial Advisors sold 227 Vertex Pharmaceuticals shares in Q1 2026, an estimated $106K.
  • Vertex Pharmaceuticals made up 0.36% of Brown Financial Advisors's portfolio in Q1 2026, its #82 holding.
  • Brown Financial Advisors first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Brown Financial Advisors's Vertex Pharmaceuticals position peaked at $1.07M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Brown Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.